Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Sold by Royce & Associates LP

Royce & Associates LP reduced its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 56.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 312,184 shares of the company's stock after selling 398,303 shares during the period. Royce & Associates LP owned approximately 0.15% of Cellebrite DI worth $6,877,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Quarry LP purchased a new stake in Cellebrite DI in the 3rd quarter worth approximately $27,000. Advisors Asset Management Inc. boosted its holdings in Cellebrite DI by 130.5% during the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company's stock worth $52,000 after buying an additional 1,742 shares in the last quarter. R Squared Ltd acquired a new stake in Cellebrite DI during the fourth quarter valued at $100,000. Victory Capital Management Inc. purchased a new position in Cellebrite DI in the fourth quarter valued at $234,000. Finally, HighTower Advisors LLC purchased a new position in Cellebrite DI in the fourth quarter valued at $274,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Analysts Set New Price Targets

CLBT has been the subject of several recent analyst reports. JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Lake Street Capital raised their price objective on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a research note on Monday, March 10th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $23.43.

Remove Ads

Cellebrite DI Stock Up 1.0 %

Shares of Cellebrite DI stock traded up $0.19 during mid-day trading on Friday, reaching $19.23. 943,485 shares of the stock traded hands, compared to its average volume of 1,121,166. The business has a 50-day moving average of $21.12 and a 200 day moving average of $19.76. The stock has a market capitalization of $4.61 billion, a PE ratio of -13.83, a PEG ratio of 4.27 and a beta of 1.52. Cellebrite DI Ltd. has a fifty-two week low of $10.25 and a fifty-two week high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, equities research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.